Viking Therapeutics announced that it has commenced an underwritten public offering of $350M of shares of its common stock. All of the shares of common stock to be sold in the proposed offering are to be sold by Viking. Viking currently intends to use the net proceeds from the proposed offering for continued development of its VK2809, VK2735 and VK0214 programs and for general research and development, working capital and general corporate purposes. Morgan Stanley, Leerink Partners, William Blair, Raymond James, Stifel and Truist Securities are acting as joint book-running managers for the proposed offering.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on VKTX:
- Viking Therapeutics Issues Regulation FD Disclosure Notice
- Viking Therapeutics call volume above normal and directionally bullish
- Viking Therapeutics rumor highlighted again by Betaville blog
- Viking Therapeutics price target raised to $35 from $30 at Stifel
- Viking Therapeutics price target raised to $38 from $32 at Truist